Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682776 | 0.83 | ADORA2B (0.50) | ADORA2BLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL683913 | 0.80 | RXFP1 (0.55) | ADORA2BLMNASMN1; SMN2MAPTRXFP1 | |
| Fenethylline SCHEMBL149145 | 0.79 | ALDH1A1 (0.65) | ADORA2BLMNASMN1; SMN2MAPTALDH1A1 | |
| Fenethylline SCHEMBL28154439 | 0.79 | SMN1; SMN2 (0.55) | ADORA2BLMNASMN1; SMN2MAPTALDH1A1 | |
| Fenethylline SCHEMBL155920 | 0.79 | ALDH1A1 (0.64) | ADORA2BLMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL684285 | 0.79 | RXFP1 (0.53) | ADORA2BLMNASMN1; SMN2MEN1KMT2A | |
| Fenethylline SCHEMBL121386 | 0.79 | ALDH1A1 (0.64) | ADORA2BLMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL683985 | 0.78 | ALOX15 (0.56) | ADORA2BLMNASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL684309 | 0.78 | ALDH1A1 (0.50) | ADORA2BSMN1; SMN2ALDH1A1MAPK1RXFP1 | |
| SCHEMBL682774 | 0.78 | LMNA (0.66) | ADORA2BLMNASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ADORA2B 786/4885LMNA 2155/4885SMN1; SMN2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.